KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Treasury Shares (2016 - 2025)

Travere Therapeutics' Treasury Shares history spans 13 years, with the latest figure at $4.6 million for Q4 2025.

  • For Q4 2025, Treasury Shares rose 2012.49% year-over-year to $4.6 million; the TTM value through Dec 2025 reached $4.6 million, up 2012.49%, while the annual FY2025 figure was $4.6 million, 2012.49% up from the prior year.
  • Treasury Shares reached $3.2 million in Q4 2014 per TVTX's latest filing, roughly flat from $3.2 million in the prior quarter.
  • In the past five years, Treasury Shares ranged from a high of $4.6 million in Q4 2025 to a low of $216208.0 in Q4 2024.
  • Average Treasury Shares over 5 years is $2.3 million, with a median of $2.3 million recorded in 2022.
  • The largest YoY upside for Treasury Shares was 235.85% in 2014 against a maximum downside of 235.85% in 2014.
  • A 2-year view of Treasury Shares shows it stood at $957272.0 in 2013, then skyrocketed by 235.85% to $3.2 million in 2014.
  • Per Business Quant, the three most recent readings for TVTX's Treasury Shares are $4.6 million (Q4 2025), $216208.0 (Q4 2024), and $2.9 million (Q4 2023).